• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women with ADHD face a difficult decision regarding whether or not to stop taking ADHD medication during pregnancy and breastfeeding. There are few data regarding how exposure over time may affect a pregnant fetus.

A study recently published in Molecular Psychiatry shows that children exposed to ADHD medication during the uterus don't develop neurological conditions like hearing or vision impairment seizures, febrile seizures, or IQ impairment. The authors acknowledge that further high-quality studies are required.

Risk/Benefit Analysis

Pregnant women who use ADHD medications need to balance the advantages of taking them against potential risks to the fetus. The doctors don't have the information to make unambiguous recommendations but they can provide information about risks and benefits to aid pregnant women in making an informed decision.

A study published in Molecular Psychiatry found that women who were taking ADHD medications in early pregnancy did not have a significantly increased risk of fetal cardiac malformations or major structural birth defects. Researchers conducted a large population-based case control study to compare the incidence of structural defects that were major in infants who were born to mothers who used stimulants during pregnancy. Clinical geneticists and pediatric cardiologists examined the cases to ensure correct classification of the cases and to reduce the chance of bias.

The study of the researchers had some limitations. Researchers were unable, in the first place to distinguish the effects caused by the medication from the disorder. This makes it difficult to know whether the small associations observed in the groups that were exposed are due to medication use or confounding by comorbidities. Researchers also did not examine the long-term effects for the offspring.

The study did reveal that babies whose mothers had taken ADHD medications during pregnancy were at a higher risk of being admitted to the neonatal intensive care unit (NICU) than those who whose mothers did not take any medication or had stopped their medications before or during pregnancy. This was due to central nervous system disorders. The higher risk of admission was not influenced by the stimulant medications used during pregnancy.

Women who took stimulant ADHD medications during pregnancy also had a higher likelihood of having caesarean sections or a baby that scored low on the Apgar scale (less than 7). These increases appeared to be independent of the type of medication taken during pregnancy.

Researchers suggest that the small risk of using ADHD medication during pregnancies in the early stages could be offset by the greater benefits for mother and baby from continuing treatment for the woman’s disorder. Physicians should discuss this with their patients and, when possible, help them develop strategies to improve coping skills that may minimize the negative impact of her condition on her daily life and relationships.

Medication Interactions

Many doctors are faced with the decision of whether to continue treatment or stop it during pregnancy as more women are diagnosed with ADHD. These decisions are often taken without clear and authoritative evidence. Instead, doctors must take into account their own experience, the experience of other doctors and the research on the subject.

Particularly, the issue of potential risks to the baby can be a challenge. Many of the studies on this issue are based on observations instead of controlled research and their conclusions are often contradictory. Furthermore, most studies restrict their analysis to live births, which could underestimate the severity of teratogenic effects that could lead to abortion or termination of the pregnancy. The study that is discussed in the journal club addresses these limitations by analyzing data on live and deceased births.

Conclusion: While some studies have found a positive correlation between ADHD medications and certain birth defects, other studies have not established a link. Most studies show that there is a neutral, or somewhat negative, effect. In each case it is imperative to conduct a thorough evaluation of the potential risks and benefits should be conducted.

It can be challenging, if not impossible, for women suffering from ADHD to stop taking their medication. In an article published in Archives of Women's Mental Health psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can cause depression, feelings of isolation and family conflict for those suffering from the disorder. A decrease in medication could affect the ability to drive safely and complete work-related tasks, which are vital aspects of daily life for people with ADHD.

She suggests women who are adhd meds covered by ohip uncertain about whether or not to stop medication in light of their pregnancy consider the possibility of educating friends, family members and colleagues on the condition, its effects on daily functioning, and the advantages of continuing the current treatment plan. It can also help the woman feel supported as she struggles with her decision. It is important to note that certain medications can pass through the placenta therefore, if a patient decides to stop taking her best adhd medication uk medication during pregnancy and breastfeeding, she must be aware of the possibility that traces of the drug can i get adhd meds without a diagnosis be transferred to the child.

Risk of Birth Defects

As the use of ADHD medications to treat symptoms of attention deficit hyperactivity disorder (ADHD) grows there are concerns about what impact the drugs might have on the fetuses. A study that was published in the journal Molecular Psychiatry adds to the existing knowledge about this subject. Utilizing two huge data sets researchers were able analyze more than 4.3 million pregnancies and see whether the use of stimulant medications increased the risk of birth defects. Although the risk overall remains low estrogen and adhd medication, the researchers discovered that the first-trimester exposure to ADHD medicines was associated with a slightly higher rate of certain heart defects, such as ventriculo-septal defect (VSD).

The researchers behind the study found no association between the use of early medications and other congenital abnormalities, like facial clefting, or club foot. The findings are in line with previous studies showing a small but significant increase in the risk of heart malformations among women who began taking ADHD medications prior to the time of the birth of their child. The risk was higher during the latter part of pregnancy, when many women begin to discontinue their uk adhd medication medications.

Women who were taking ADHD medication in the first trimester were more likely to require a caesarean birth and also have an insufficient Apgar after delivery, and had a baby that required help breathing after birth. However the authors of the study were not able to eliminate bias due to selection by restricting the study to women who didn't have any other medical conditions that could have contributed to the findings.

The researchers hope that their research will aid in the clinical decisions of physicians who see pregnant women. They suggest that although discussing risks and benefits is important however, the decision to stop or maintain treatment should be based on each woman's requirements and the severity of her ADHD symptoms.

The authors also caution that while discontinuing the medications is an alternative, it is not an option to consider due to the high incidence of depression and other mental health problems in women who are pregnant or recently postpartum. Furthermore, research suggests that women who choose to stop their medications are more likely to have difficulties getting used to life without them following the birth of their baby.

Nursing

It can be a stressful experience to become a mom. Women who suffer from ADHD who have to deal with their symptoms while attending physician appointments and preparing for the arrival of a child and getting used to new routines at home can experience severe challenges. Therefore, many women decide to continue taking their ADHD medications throughout the course of pregnancy.

The majority of stimulant drugs are absorbed by breast milk in very small amounts, so the risk to infant who is breastfeeding is low. The rate of medication exposure will differ based on dosage, frequency of administration and time of day. In addition, different types of adhd medication medications enter the baby’s system through the gastrointestinal tract, or through breast milk. The impact of these medications on the health of a newborn is not completely understood.

Due to the absence of research, some physicians may recommend stopping stimulant medication during the course of pregnancy. This is a difficult choice for the patient, who must weigh the benefits of keeping her medication against the possible risks to the fetus. As long as there is no more information, doctors should ask all pregnant patients about their experience with ADHD and whether they are planning or taking to take medication during the perinatal period.

Numerous studies have proven that women can continue taking their ADHD medication safely while breastfeeding and during pregnancy. This has led to many patients opt to do this and, in consultation with their physician, they have found that the benefits of maintaining their current medication far outweigh any risks.

Women with ADHD who plan to breastfeed should seek advice from an expert psychiatrist prior to becoming pregnant. They should review their medications with their prescriber and discuss the pros and cons of continued treatment, including non-pharmacological management strategies. Psychoeducation should also be offered to help women with ADHD be aware of their symptoms and the root cause Learn about the available treatment options and strengthen existing coping strategies. This should be a multidisciplinary process with the GPs, obstetricians, and psychiatrists. The pregnancy counselling should consist of discussion of a management plan for both the mother as well as the child, as well as monitoring for signs of deterioration and when necessary, making adjustments to the medication regimen.